The shift towards a more bullish outlook by analysts, as evidenced by the increased average price target, suggests a positive short-term impact on BMRN's stock price. However, the underlying financial challenges such as below-industry profitability and efficiency metrics could temper the extent of positive movement. The recent approval of Roctavian in the US and Europe indicates potential for future revenue growth, which may be factoring into analysts' improved outlook.